Clopidogrel

Clopidogrel

Systematic (IUPAC) name
(+)-(S)-methyl 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetate
Clinical data
Trade names	Plavix
AHFS/Drugs.com	monograph
MedlinePlus	a601040
Pregnancy cat.	B1(AU) B(US)
Legal status	Prescription Only (S4) (AU) POM (UK) ℞-only (US)
Routes	Oral
Pharmacokinetic data
Bioavailability	>50%
Protein binding	94–98%
Metabolism	Hepatic
Half-life	7–8 hours (inactive metabolite)
Excretion	50% renal 46% biliary
Identifiers
CAS number	113665-84-2 Y
ATC code	B01AC04
PubChem	CID 60606
DrugBank	APRD00444
ChemSpider	54632 Y
UNII	A74586SNO7 Y
KEGG	D07729 Y
ChEBI	CHEBI:37941 Y
ChEMBL	CHEMBL1771 Y
Chemical data
Formula	C16H16ClNO2S
Mol. mass	321.82 g/mol
SMILES	eMolecules & PubChem
InChI InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1 Y Key:GKTWGGQPFAXNFI-HNNXBMFYSA-N Y
N(what is this?)  (verify)

Clopidogrel (INN) is an oral, thienopyridine class antiplatelet agent used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease. It is marketed by Bristol-Myers Squibb and Sanofi under the trade name Plavix. The drug works by irreversibly inhibiting a receptor called P2Y₁₂, an adenosine diphosphate (ADP) chemoreceptor on platelet cell membranes. Adverse effects include hemorrhage, severe neutropenia, and thrombotic thrombocytopenic purpura (TTP).

Pharmacology

Clopidogrel is a prodrug, the action of which may be related to an ADP receptor on platelet cell membranes. The drug specifically and irreversibly inhibits the P2Y₁₂ subtype of ADP receptor, which is important in aggregation of platelets and cross-linking by the protein fibrin.^[1] The blockade of this receptor inhibits platelet aggregation by blocking activation of the glycoprotein IIb/IIIa pathway. The IIb/IIIa complex functions as a receptor mainly for fibrinogen and vitronectin but also for fibronectin and von Willebrand factor. Activation of this receptor complex is the "final common pathway" for platelet aggregation and is important in the cross-linking of platelets by fibrin.

Platelet inhibition can be demonstrated two hours after a single dose of oral clopidogrel, but the onset of action is slow, so that a loading-dose of 300–600 mg is usually administered.

Clinical use

Indications

Clopidogrel is indicated for:^[2]

• Prevention of vascular ischemic events in patients with symptomatic atherosclerosis
• Acute coronary syndrome without ST-segment elevation (NSTEMI),
• ST elevation MI (STEMI)

It is also used, along with aspirin, for the prevention of thrombosis after placement of intracoronary stent^[2] or as an alternative antiplatelet drug for patients who are intolerant to aspirin.^[3]

International guidelines granted the highest grade of recommendation for NSTE-ACS, PCI and stent,^{[clarification needed]} for clopidogrel in addition to aspirin. Consensus-based therapeutic guidelines recommend also the use of clopidogrel, instead of aspirin, in patients requiring antiplatelet therapy but with a history of gastric ulceration, as inhibition of the synthesis of prostaglandins by aspirin (acetylsalicylic acid) can exacerbate this condition. A study has shown that in patients with healed aspirin-induced ulcers, however, patients receiving aspirin plus the proton pump inhibitor esomeprazole had a lower incidence of recurrent ulcer bleeding than patients receiving clopidogrel.^[4] However, a more recent study suggested that prophylaxis with proton pump inhibitors along with clopidogrel following acute coronary syndrome may increase adverse cardiac outcomes, possibly due to inhibition of CYP2C19, which is required for the conversion of clopidogrel to its active form.^[5][6][7] The European Medicines Agency has issued a public statement on a possible interaction between clopidogrel and proton pump inhibitors.^[8] However, several cardiologists have voiced concern that the studies on which these warnings are based have many limitations and that it is not certain whether there really is an interaction between clopidogrel and proton pump inhibitors.^[9]

Dosage forms

Clopidogrel is marketed as clopidogrel bisulfate (clopidogrel hydrogen sulfate), most commonly under the trade names Plavix, as 75 mg oral tablets.

Pharmacokinetics and metabolism

Clopidogrel (top left) being activated. The first step is an oxidation mediated (mainly) by CYP2C19, unlike the activation of the related drug prasugrel. The two structures at the bottom are tautomers of each other; and the final step is a hydrolysis. The active metabolite (top right) has Z configuration at the double bond C3–C16 and possibly R configuration at the newly asymmetric C4.^[10]

After repeated 75 mg oral doses of clopidogrel (base), plasma concentrations of the parent compound, which has no platelet inhibiting effect, are very low and are generally below the quantification limit (0.258 µg/L) beyond two hours after dosing.

Clopidogrel is a pro-drug activated in the liver by cytochrome P450 enzymes, including CYP2C19. Due to opening of the thiophene ring, the chemical structure of the active has three sites that are stereochemically relevant, making a total of eight possible isomers. These are: a stereocentre at C4 (attached to the —SH thiol group), a double bond at C3—C16, and the original stereocentre at C7. Only one of the eight structures is an active antiplatelet drug. This has the following configuration: Z configuration at the C3—C16 double bond, the original S configuration at C7,^[10] and although the stereocentre at C4 can't be directly determined, as the thiol group is too reactive, work with the active metabolite of the related drug prasugrel suggests that R-configuration of the C4 group is critical for P2Y₁₂ and platelet-inhibitory activity.^{[citation needed]}

The active metabolite has an elimination half-life of about eight hours and acts by forming a disulfide bridge with the platelet ADP receptor. Patients with a variant allele of CYP2C19 are 1.5 to 3.5 times more likely to die or have complications than patients with the high-functioning allele.^[11][12][13]

Following an oral dose of ¹⁴C-labeled clopidogrel in humans, approximately 50% was excreted in the urine and approximately 46% in the feces in the five days after dosing.

Effect of food: Administration of clopidogrel bisulfate with meals did not significantly modify the bioavailability of clopidogrel as assessed by the pharmacokinetics of the main circulating metabolite.

Absorption and distribution: Clopidogrel is rapidly absorbed after oral administration of repeated doses of 75 mg clopidogrel (base), with peak plasma levels (approx. 3 mg/L) of the main circulating metabolite occurring approximately one hour after dosing. The pharmacokinetics of the main circulating metabolite are linear (plasma concentrations increased in proportion to dose) in the dose range of 50 to 150 mg of clopidogrel. Absorption is at least 50% based on urinary excretion of clopidogrel-related metabolites. Clopidogrel and the main circulating metabolite bind reversibly in vitro to human plasma proteins (98% and 94%, respectively). The binding is nonsaturable in vitro up to a concentration of 110 μg/mL.

Metabolism and elimination: In vitro and in vivo, clopidogrel undergoes rapid hydrolysis into its carboxylic acid derivative. In plasma and urine, the glucuronide of the carboxylic acid derivative is also observed.

In March 2010, the U.S. Food and Drug Administration (FDA) added a boxed warning to Plavix alerting that the drug can be less effective in people who cannot metabolize the drug to convert it to its active form.^[14][15]

Pharmacogenetics

CYP2C19 is an important drug-metabolizing enzyme that catalyzes the biotransformation of many clinically useful drugs including antidepressants, barbiturates, proton pump inhibitors, antimalarial and antitumor drugs. Clopidogrel is one of the drugs metabolized by this enzyme.

Several recent landmark studies have proven the importance of 2C19 genotyping in treatment using clopidogrel or Plavix. In March 2010, the FDA put a black box warning on Plavix to make patients and healthcare providers aware that CYP2C19 poor metabolizers, representing up to 14% of patients, are at high risk of treatment failure and that testing is available.^[16] Researchers have found that patients with variants in cytochrome P-450 2C19 (CYP2C19) have lower levels of the active metabolite of clopidogrel, less inhibition of platelets, and a 3.58 times greater risk for major adverse cardiovascular events such as death, heart attack, and stroke; the risk was greatest in CYP2C19 poor metabolizers.^[17]

Adverse effects

Serious adverse drug reactions associated with clopidogrel therapy include:

• Severe neutropenia (low white blood cells) (Incidence: 1/2,000)
• Thrombotic thrombocytopenic purpura (TTP) (Incidence: 4/1,000,000 patients treated)^[18][19]
• Hemorrhage - The annual incidence of hemorrhage may be increased by the co-administration of aspirin.^[20]
  • Gastrointestinal Hemorrhage (Incidence: 2.0% annually)
  • Cerebral Hemorrhage (Incidence: 0.1 to 0.4% annually)
  • Use of non-steroidal anti-inflammatory drugs is discouraged in those taking clopidogrel due to increased risk of digestive tract hemorrhage
• Most studies reseaching clopidogrel do not compare patients on clopidogrel to patients taking placebo, rather clopidogrel use is compared to aspirin use. Thus attributing side effects directly to clopidogrel is difficult. Other side effects may include:
  • Other gastrointestinal side effects
    • Upper GI discomfort (27% vs 29% in patients taking aspirin alone)
    • Gastric or duodenal ulcer, gastritis
    • Diarrhea (4.5% of patients in the CAPRIE trial)^[21]
  • Rash (6% overall, 0.33% severe)^[22]
  • Respiratory (infrequent)
    • Upper respiratory infections, rhinitis, shortness of breath, cough
  • Cardiovascular
    • chest pain
    • edema (generalized swelling)

Interactions

Clopidogrel interacts with the following drugs: proton pump inhibitors (except possibly pantoprazole), phenytoin (Dilantin); tamoxifen (Nolvadex); tolbutamide (Orinase); torsemide (Demadex); fluvastatin (Lescol); a blood thinner such as warfarin (Coumadin), heparin, ardeparin (Normiflo), dalteparin (Fragmin), danaparoid (Orgaran), enoxaparin (Lovenox), or tinzaparin (Innohep); (Activase), anistreplase (Eminase), dipyridamole (Persantine), streptokinase (Kabikinase, Streptase), ticlopidine (Ticlid), and urokinase (Abbokinase).

In November 2009, the FDA announced that clopidogrel should not be taken with proton pump inhibitors such as omeprazole and esomeprazole.^[23][24]

Marketing and litigation

A box of Plavix

Plavix is marketed worldwide in nearly 110 countries, with sales of US$6.6 billion in 2009.^[25] It had been the 2nd top selling drug in the world for a few years as of 2007^[26] and was still growing by over 20% in 2007. U.S. sales were US$3.8 billion in 2008.^[27]

In 2006, generic clopidogrel was briefly marketed by Apotex, a Canadian generic pharmaceutical company before a court order halted further production until resolution of a patent infringement case brought by Bristol-Myers Squibb.^[28] The court ruled that Bristol-Myers Squibb's patent was valid and provided protection until November 2011.^[29] More recently, the FDA extended the patent protection of clopidogrel by six months, giving exclusivity that would expire on May 17, 2012.^[30]

Generic clopidogrel is also produced by several pharmaceutical companies in India and elsewhere, and often sold under its INN clopidogrel. Clopidogrel is marketed by Sun Pharmaceuticals under the trade name Clopilet, by Ranbaxy Laboratories under the trade name Ceruvin, and under the name "Clavix" by Intas Pharmaceuticals and under the name "Deplatt" by Torrent Pharmaceuticals. In India, it is sold as Clopigrel, Clopitab, Clopijoy, and Clasprin (mixed with aspirin).

References

External links

• 3418 drug label/data at Daily Med from U.S. National Library of Medicine, National Institutes of Health.
• Plavix official website Bristol-Myers Squibb/Sanofi-Aventis
• Plavix prescribing information Bristol-Myers Squibb/Sanofi-Aventis
• Plavix, Aspirin and Stents : Patients' Forum : Angioplasty.Org
• Drug promises end to migraine misery
• U.S. National Library of Medicine: Drug Information Portal - Clopidogrel